In the journal Cancer Discovery, UNC Lineberger researchers Gary Johnson, PhD, and Lisa Carey, MD, and colleagues report findings of just how triple negative breast cancer cells are able to bypass treatment with trametinib, a U.S. Food and Drug Administration-approved drug that belongs to a class of commonly used anti-cancer drugs called kinase inhibitors. The researchers also reported findings from laboratory models of breast cancer testing a potential treatment approach that could prevent the onset of resistance.
A team of researchers, including UNC Lineberger's Norman E. Sharpless, MD, has shown that chemotherapy triggers a pro-inflammatory stress response termed cellular senescence, promoting the adverse effects of chemotherapy as well as cancer relapse and metastasis. Eliminating the senescent cells in mice prevented the side effects and relapse.
Backed by a three-year, more than $1.8 million grant from the National Cancer Institute, UNC Lineberger researchers Ryan Miller, MD, PhD, and Gary Johnson, PhD, plan to develop better cancer models to identify patterns of drug resistance in glioblastoma.
In a perspective published in the New England Journal of Medicine, UNC Lineberger member Ethan Basch, MD, MSc, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.